MAIA (MAIA Biotechnology) Long-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Long-Term Debt?

MAIA Biotechnology's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

MAIA Biotechnology Long-Term Debt Historical Data

The historical data trend for MAIA Biotechnology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Long-Term Debt Chart

MAIA Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

0.43

MAIA Biotechnology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial											-	-	-	-	-

MAIA Biotechnology (AMEX:MAIA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

MAIA Biotechnology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060

Website

https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Executives

Steven M Chaouki	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Stan Smith	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie	director, 10 percent owner	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc	director, 10 percent owner, officer: Chief Executive Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire	officer: Chief Financial Officer	6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene	director	500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov	officer: Chief Scientific Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea	officer: Chief Medical Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606